<DOC>
	<DOC>NCT01164904</DOC>
	<brief_summary>To assess the safety and tolerability of single subcutaneous (SC) and intravenous (IV) doses of AMG 181 in healthy subjects and of a single SC dose in subjects with mild to moderate ulcerative colitis (UC)</brief_summary>
	<brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Healthy Volunteers Healthy male or female subjects of nonreproductive potential between 18 to 45 yearof age Body Mass Index (BMI) between 18 and 34 kg/m2 Normal physical and neurological examination, clinical laboratory values and ECG Additional inclusion criteria apply Subjects with Mild to Moderate Ulcerative Colitis Male or female subjects between 18 to 55 yearof age Body Mass Index (BMI) between 18 and 34 kg/m2 Diagnosis of Ulcerative Colitis for at least 2 months Active, mild to moderate disease as defined by an Ulcerative Colitis Disease Activity Index (UCDAI, aka Mayo score) score of 4 to 9 (inclusive), with a minimum sigmoidoscopy score of 1 Additional inclusion criteria apply Exclusion criteria: Healthy Volunteers History or evidence of a clinically significant disorder (including psychiatric), condition or disease that would pose a risk to subject safety or interfere with the study evaluations, procedures or completion History of malignancy of any type, other than in situ cervical cancer or surgically excised nonmelanomatous skin cancers within the past 5 years Recent or ongoing infection(s) Underlying condition(s) that predisposes the subject to infections Additional exclusion criteria apply Exclusion criteria: Subjects with Mild to Moderate Ulcerative Colitis Disease limited to the rectum, i.e. within 20 cm of the anal verge Any prior gastrointestinal surgery Evidence of severe disease (as evidenced by an Hb concentration &lt;11g/dL; toxic megacolon, or an UCDAI scoreâ‰¥10) Immunosuppressive therapy with either azathioprine, methotrexate, or mercaptopurine, within the past 3 months Prior exposure to a biologic agent or cyclosporine A Use of antibiotics within the past 2 weeks of screening and during screening period Use of topical (e.g. suppository or enema) mesalamine or steroids within two weeks prior to day 1 Additional exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>Amgen</keyword>
</DOC>